Clinical trial
Phase 2 Trial of a Nicotinic Agonist in Schizophrenia
NCT00100165 · University of Colorado, Denver, Other · Completed
Key facts
| NCT number | NCT00100165 |
|---|---|
| Title | Phase 2 Trial of a Nicotinic Agonist in Schizophrenia |
| Official title | Phase 2 Trial of the Nicotinic Agonist 3-(2,4 Dimethoxybenzylidene Anabaseine) in Schizophrenia |
| Acronym | DMXB-A |
| Lead sponsor | University of Colorado, Denver, Other |
| Collaborators | VA Office of Research and Development U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Placebo, 3-(2, 4 dimethoxybenzylidene anabaseine) 150 mg, 4 dimethoxybenzylidene anabaseine) 75 mg |
| Enrollment | 29 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Dec 24, 2004 |
| Last update posted | Jan 29, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: